SMA Data Update

 SMA Data update with Biogen.   Dear members of the SMA community, Following your request for updates regarding new SMA data in adult patients, we wanted to share that a real-world study of nusinersen (SPINRAZA ™) use in teens and adults with SMA was published in The Lancet Neurology on March 18, 2020 in a…

Nova Scotia broadens access to SPINRAZA™ (nusinersen injection)Cure SMA Canada is recognized for our contribution to the Canadian government’s understanding of the impact of SMA

Cure SMA Canada is recognized for our contribution to the Canadian government’s understanding of the impact of SMA and played a major role in the associated changes to access to treatment brought by this contribution. Thank you to all of those who participated and supported Cure SMA Canada initiatives!  Together we truly do make a…

Biogen Press Release

Press Release   NURTURE study shows pre-symptomatic Spinal Muscular Atrophy (SMA) infants treated with SPINRAZA™ (nusinersen injection) attained positive results ▪ Treatment with SPINRAZA™ resulted in survival of 100 percent of infants and none requiring permanent ventilation ▪ Recently published outcomes include motor milestones achieved in 100 percent of infants sitting withoutsupport and 88 percent…

Ontario Expands Coverage of Spinraza!!

Ontario Government got it right!! We at Cure SMA Canada are very happy and proud to announce that the government of the province of Ontario has communicated with us that they have come to a mutually agreeable decision to approve reimbursement for Ontario’s Spinal Muscular Atrophy patients. As a follow-up to the national review process…

Roche Community Update

5 July 2018 Dear SMA community members, As requested, we are very pleased to share with you an update of the RG7916 programme, which has reached a number of milestones. We would also like to extend special thanks to study participants and their families for their incredible commitment to advancing the progress of research in…